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Abstract
Purpose To describe CT characteristics of primary pancreatic
lymphoma (PPL), a rare disease with features in commonwith
adenocarcinoma.
Materials and methods Fourteen patients were enrolled. CT:
unenhanced scan, contrast-enhanced pancreatic and venous
phases. Image analysis: tumour location; peri-pancreatic ves-
sel encasement; necrosis; enlarged lymph nodes; fat stranding;
enlarged bile duct and pancreatic duct; neoplasm longest di-
mension, volume and density.
Results Histopathological diagnoses: follicular non-Hodgkin
lymphoma (5/14), diffuse large B-cell lymphoma (6/14) and
high-grade B-cell lymphoma not otherwise specified (3/14).
Six of 14 PPLs were located in the pancreatic head and 7/14 in
the body-tail; 1/14 involved the whole gland. In 5/14 cases the
superior mesenteric artery and vein were encased; splenic vein
and artery encasement was depicted in 2 PPLs. Necrosis was
present in 2/14. Enlarged retroperitoneal lymph nodes were
found in 11 cases and fat stranding in all patients. The bile duct
was dilated in six cases and the pancreatic duct in five. Mean
neoplasm longest diameter and volume were 8.05 cm and
210.8 cm3. Mean tumour attenuation values were 39.1 HU
at baseline, 60.6 HU in the pancreatic phase and 71.4 HU in
the venous phase.
Conclusions PPL presents as a large mass lesion with delayed
homogeneous enhancement; peri-pancreatic fat stranding and
vessel encasement are present, without vascular infiltration.
Pancreatic duct dilatation is rare.
Key points
• Primary pancreatic lymphoma (PPL) is a rare haematological
disease
• PPL presents imaging features in common with pancreatic
carcinoma but also some distinctive findings
• The majority of PPLs are large lesions with delayed
homogeneous enhancement
• Peri-pancreatic fat stranding and vessel encasement are
common in PPL
• Vascular infiltration and pancreatic duct dilatation are rare
in PPL
Keywords Pancreas . Lymphoma . Imaging . Computed
tomography . Differential diagnosis
Introduction
Primary pancreatic lymphoma (PPL) is a very rare disease,
representing only 0.1% of malignant lymphomas and 0.2%
of primary pancreatic tumours [1, 2]. The World Health
Organisation provides precise diagnostic criteria: the bulk
of the disease is localised in the pancreas; adjacent lymph
node involvement and distant spread may exist but the pri-
mary clinical presentation has to involve the pancreatic gland
[3]. The disease can develop at any age, but usually affects
elderly patients, with higher incidence in males. Clinical
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presentation is variable: in most cases the first manifestation
is abdominal pain; other clinical findings include systemic
symptoms such as fever, night sweats and weight loss.
Jaundice and/or gastric or duodenal obstruction may be pres-
ent [2]. These heterogeneous symptoms may overlap those of
other pancreatic tumours, resulting in diagnostic difficulties
[4, 5]. Histopathological examinations reveal a framework
compatible with non-Hodgkin lymphoma, usually diffuse
large B cell lymphoma (DLBCL). Nevertheless, other histo-
logical types have been reported including indolent diseases
such as follicular and marginal zone lymphoma [3–6].
Diagnosis can be obtained through a percutaneous/
endoscopic US-guided biopsy or exploratory laparotomy bi-
opsy. The correct diagnosis is essential because, unlike epi-
thelial tumours, patients with lymphoma do not benefit from
surgery but from chemotherapy and indeed surgery may in-
crease morbidity [5].
Up to now, reports of the CT imaging appearance of PPL
are limited to a few papers including mainly case reports
[7–10]. The aim of this study is to describe the imaging char-
acteristics of PPL at CT based on a relatively large series of
cases examined in three institutions in three different countries.
Materials and methods
Patient population
The Institutional Review Board (IRB) of the coordinating
centre approved the research proposal. The IRB stated that
this retrospective study was in compliance with the 1964
Helsinki Declaration and its later amendments, and the re-
quirement for informed patient consent was waived. All pa-
tients with a histopathological diagnosis of PPL observed
from January 2010 to July 2017 in three different institutes,
all referral centres for pancreatic diseases (namely, centre A,
coordinating centre; centre B; centre C) were evaluated.
Patients were identified searching the medical record data-
bases of radiology, pathology and surgery. Inclusion criteria
were: the availability, for each patient, of one contrast-
enhanced CT examination performed in one of the centres
before the start of chemotherapy and a histopathological con-
firmation of the diagnosis. We excluded patients affected by a
lymphoma located in other organs with secondary pancreatic
involvement.
Thus, our study population consisted of 14 Caucasian
patients: 7 examined in centre A, 5 in centre B and 2 in
centre C. The population included eight females and six
males, with a mean age of 62 years. The following clinical
manifestations were present: abdominal pain or discomfort
(14/14), jaundice (8/14), palpable mass (5/14) and systemic
symptoms (fever, night sweats and weight loss, 7/14 pa-
tients). Pre-treatment laboratory tests demonstrated
elevated serum lactate dehydrogenase (LDH) levels in four
patients (> 300 mU/ml). The carbohydrate antigen 19–9
(CA19–9) serum level was normal in 14 cases and only
slightly increased in 1 patient (27.15 U/ml, normal value
< 25 U/ml).
Clinical characteristics of the current study population are
summarised in Table 1.
Histopathological diagnosis was reached with biopsy of the
involved pancreas (US-guided percutaneous procedure: 6/14;
US-guided endoscopic: 7/14) or endoscopic biopsy of the
neoplasm involving the duodenum wall (1/14). All patients
were treated with polychemotherapy associated with immu-
notherapy and CD-20 antibodies.
Contrast-enhanced CT protocol
All CT examinations were performed with the same scanner
type (a 64-row multidetector CT) in the three involved cen-
tres using the same imaging protocol. Triphasic CTwas per-
formed with patients in the supine position with the arms
extended above the head. The scans included: unenhanced
scan from the dome of the liver to the lower level of the
pancreas; contrast-enhanced pancreatic parenchymal phase
using the bolus-tracking technique (trigger threshold: 200
HU, scan delay after trigger: 15 s) with the same field of
view; portal phase (70 s) from the liver dome to the symphy-
sis pubis. All patients received 1.5 ml per kilogram of body
weight intravenous iodinated contrast agent (Ultravist 370;
Bayer Schering Pharma, Leverkusen, Germany) at an injec-
tion rate of 4 ml/s using an automatic injector through an
antecubital vein and followed by 40–50 ml of saline solution
chase at the same flow rate. Other scanning parameters were:
tube voltage 120 kVp; automatic tube current modulation
and slice thickness 2 mm.
Table 1 Clinical characteristics of patients affected by primary
pancreatic lymphomas (PPLs)
Parameters Number of patients (n = 14)
Age
• Mean 62 years
• Range 41–85 years
Gender
• Male 6 (42.9%)
• Female 8 (57.1%)
Symptoms
• Abdominal pain or discomfort 14 (100%)
• Jaundice 8 (57.1%)
• Palpable mass 5 (35.7%)
• Systemic symptoms 7 (50.0%)
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Image analysis
The imaging data obtained from MDCT were processed on
commercially available workstations. In each participating
centre one radiologist (radiologist A, with 12 years of
experience in abdominal imaging; radiologist B, 13 years
of experience; radiologist C, 12 years of experience)
analysed the images from their own institution. A fourth
radiologist from the coordinating centre, with 5 years of
experience in abdominal imaging, assessed the data
Fig. 1 A 42-year-old male patient with primary pancreatic lymphoma,
histotype diffuse large B-cell lymphoma (Ki 67 score > 95%). a. CT scan
of the abdomen shows the presence of a large solid mass involving the
pancreatic body and tail (arrow); the lesion reaches the spleen and almost
encases it. b, cCTimages after contrast medium administration in the arterial-
pancreatic phase (a) and portal-venous phase (b): the neoplasm is hypodense,
with progressive contrast enhancement. d. This coronal CT reconstruction
allows better appreciation of the size and extension of the lesion (arrows)
Table 2 Histopathological
results Histotype Number of patients (n = 14)
• Follicular non-Hodgkin lymphoma 5
• Diffuse large B-cell lymphoma (DLBCL) 6
• High-grade B-cell lymphoma not otherwise specified 3
Replicative Ki67 index score
• Ki67 ≤ 25% 2
• 25% <Ki67 ≤ 50% 4
• 50% <Ki67 ≤ 75% 1
• 75% <Ki67 ≤ 100% 7
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collected by the other radiologists to avoid inhomogeneities
in the analyses. Qualitative analysis included: tumour loca-
tion (head, body-tail or the whole pancreatic gland); pres-
ence of major peri-pancreatic vessel encasement (defined
as circumferential involvement of the vessel [11]), in partic-
ular the caeliac axis, superior mesenteric artery, common
hepatic artery, gastroduodenal artery, portal vein, superior
mesenteric vein and splenic vein; presence of necrosis within
the tumour (regions with attenuation between 10 and 30 HU
in the unenhanced scan, without contrast enhancement [12]);
presence of enlarged abdominal lymph nodes (shot axis >
10 mm); presence of fat stranding in the peri-pancreatic re-
gion (defined as abnormally increased attenuation in the fat,
suggestive of infiltration of the mesenteric lymphatic vessels
[13]); presence of an enlarged common bile duct (calibre >
10 mm); presence of an enlarged main pancreatic duct up-
stream of the neoplasm (calibre > 4 mm in the pancreatic
head or >3 in the body-tail [14]).
The assessed quantitative parameters were: neoplasm
longest dimension; volume of the lesion (calculated with
Fig. 2 A 62-year-old male patient with primary pancreatic lymphoma,
histotype high-grade B-cell lymphoma not otherwise specified (Ki 67
score > 90%). a CT scan of the abdomen shows the presence of a solid
mass in the pancreatic head (arrow). b, c, d CT images after contrast
medium administration in the arterial-pancreatic phase (a) and portal-
venous phase (b, c): the neoplasm protrudes in the duodenum (arrow),
as better demonstrated on coronal reconstruction (d). The histopatholog-
ical diagnosis was reached with endoscopic biopsy of the involved duo-
denal wall
Table 3 Results of the qualitative analysis
Parameters Number of patients (n = 14)
Site
• Head 6 (42.9%)
• Body/tail 7 (50.0%)
• Whole pancreas 1 (7.14%)
Major vessel encasement
• Caeliac axis 5 (35.7%)
• Superior mesenteric artery 5 (35.7%)
• Superior mesenteric vein 5 (35.7%)
• Splenic artery 2 (14.3%)
• Splenic vein 2 (14.3%)
Presence of necrosis 2 (14.3%)
Enlarged lymph nodes 11 (78.6%)
Peri-pancreatic fat stranding 14 (100%)
Enlarged common hepatic duct 6 (42.9%)
Enlarged main pancreatic duct 5 (35.7%)
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the ellipsoid formula: 3 main diameters × 0.52); tumour den-
sity in Hounsfield units (non-contrast, pancreatic and venous
phase).
Statistical analysis
Categorical variables are presented as numbers and percentages.
The distribution of continuous variables is reported as mean
values and standard deviations. Statistical analyses were per-
formed using MedCalc software for Windows, version 11.2.1.
Results
Histopathological results were: follicular non-Hodgkin lym-
phoma in five patients, diffuse large B-cell lymphoma
(DLBCL) in six patients and high-grade B-cell lymphoma
not otherwise specified in three patients. The replicative
Ki67 index score was below 25% in two cases, between
25% and 50% in four cases, between 50% and 75% in one
patient and more than 75% in seven cases. The histopatholog-
ical features are summarised in Table 2.
Fig. 3 A 51-year-old male patient with primary pancreatic lymphoma,
histotype diffuse large B-cell (Ki 67 score > 90%). a CT scan of the
abdomen shows the presence of a large solid mass in the body-head of
the pancreas. A biliary stent is seen. b, cCT images after contrast medium
administration in the arterial-pancreatic phase (a) and portal-venous
phase (b): the arteries and veins (arrows) are encased but not infiltrated.
The main pancreatic duct is not enlarged. d This 18FDG PET-CT fusion
image reveals high metabolic activity in the lesion
Table 4 Results of the
quantitative analysis Parameters Mean value ± standard deviation
• Longest dimension 8.05 ± 4.3 cm
• Volume 210.8 ± 308 cm3
• Attenuation value in the unenhanced scan 39.1 ± 5.9 HU
• Attenuation value in the arterial-pancreatic phase 60.6 ± 10 HU
• Attenuation value in the portal-venous phase 71.4 ± 8.7 HU
Insights Imaging (2018) 9:17–24 21
Qualitative analysis. Six out of 14 PPLs were located in the
pancreatic head and 7 in the body-tail and 1 involved the
whole gland (Figs. 1 and 2). In 5/14 cases the caeliac axis,
superior mesenteric artery and superior mesenteric vein were
encased; splenic vein and artery encasement was depicted in
two PPLs. Even when the vessels were encased, there were no
signs of infiltration, with no vessel wall irregularity or
stenoses.
Two patients had tumoral necrosis, involving respectively
about 20% and 50% of the pancreatic mass lesion. Enlarged
retroperitoneal or mesenteric lymph nodes were depicted in
11/14 cases. Fat stranding in the peri-pancreatic region was
observed in all patients. The common bile duct was dilated in
6/14 cases; the main pancreatic duct upstream of the neoplasm
was enlarged in 5/14 patients. Qualitative parameters are
summarised in Table 3.
Quantitative analysis. Mean neoplasm longest dimension
and volume were 8.05 cm and 210.8 cm3. Mean tumour at-
tenuation values were 39.1 HU in the unenhanced scan, 60.6
HU in the pancreatic phase and 71.4 HU in the venous phase
(Fig. 3). Quantitative parameters are summarised in Table 4.
Discussion
Although several case reports of PPLs have been published,
there is still little information regarding the imaging features
of these rare lesions [4, 5, 7, 8]. The current study encom-
passes 7 years of experience at three different institutions in
three different countries and describes CT and histopatholog-
ical features of 14 patients with PPL. The rarity of PPL makes
it difficult to recognise this neoplasm since it presents charac-
teristics in common with ductal adenocarcinoma, the most
frequent pancreatic solid tumour or, more rarely, with
hypovascular neuroendocrine tumours. PPL could also be
confused with the focal or diffuse forms of autoimmune pan-
creatitis; all these conditions present different management
approaches, with distinct treatment and prognosis [1, 7, 9].
Every patient in our series presented with abdominal pain
or discomfort; other frequent clinical manifestations were
jaundice, a palpable abdominal mass and systemic symptoms,
such as fever, night sweats and weight loss. Unfortunately,
pancreatic adenocarcinoma and autoimmune pancreatitis of-
ten have the same clinical picture [14]. As confirmed by the
current study, the presence of an increased LDH serum level
without an increased CA19–9 level favours a lymphomatous
aetiology of the pancreatic mass [5]. The final histopatholog-
ical diagnosis was available for every patient: the majority
were histologically aggressive DLBCL or high-grade B-cell
lymphoma not otherwise specified, with a high Ki67 index (>
75%). Only 5/14 presented low-grade malignancy (follicular
lymphomas with Ki67 < 50%). According to the literature, the
most common PPL histological subtype is DLBCL followed
by follicular lymphoma. Before the 2016WHO classification,
most high-grade B-cell lymphomas not otherwise specified
were included in the DLBCL group. Therefore, our data are
in agreement with previous studies [5, 15].
Fig. 4 A 79-year-old female patient with primary pancreatic follicular
lymphoma (Ki 67 score < 25%). a Unenhanced CT scan depicts a
hypodense mass in the pancreatic head (arrows). b, c CT images after
contrast medium administration in the arterial-pancreatic (b) and portal-
venous phase (c): progressive enhancement of the neoplasm is visible.
Enlarged retroperitoneal lymph nodes with ill-defined margins are
depicted (*)
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Some particular imaging features in patients with PPL were
observed. There was not a predilection for a pancreatic region
and the whole gland could be globally involved. Vascular en-
casement was typical, but significant irregularities in the vessels
wall were never found (Fig. 3). This peculiarity could be helpful
in the differential diagnosis with ductal adenocarcinoma, which
causes vascular infiltration at early stages, with erosion of ves-
sel walls, stenoses and eventually tumoral thrombosis [14]. The
pancreatic parenchyma affected by lymphoma has low attenu-
ation values compared to the healthy pancreas; as opposed to
adenocarcinoma, areas of necrosis are rare. After contrast me-
dium administration the attenuation is higher in the portal-
venous phase compared to the arterial-pancreatic phase
(Fig. 4). Enlarged retroperitoneal lymph nodes are frequent
and fat stranding is always present. The double duct sign, si-
multaneous dilation of the common bile and pancreatic ducts,
typical in patients with adenocarcinoma of the pancreatic head,
was only depicted in 5/14 PPLs [1, 14–17].
In the most difficult cases other imaging modalities are
recommended in addition to CT: MRI, in particular MR chol-
angiography sequences, can give important information about
ductal system morphology (a single stricture of the pancreatic
duct with an upstream enlarged duct is highly suggestive of
ductal adenocarcinoma) [16]. Evaluation of stenoses in the
ductal system could be improved by the administration of
secretin to distinguish between the infiltrated main duct (neg-
ative duct-penetrating sign after drug administration, typical
of adenocarcinoma) and compressed duct (positive duct-
penetrating sign, suggestive of a lymphomatous process)
[16]. Diffusion-weighted imaging helps to recognise the areas
of pancreatic parenchyma involved by the neoplasm and
could have a role in the evaluation of treatment response
[17]. Nuclear medicine, in particular 18FDG PET-CT, is indi-
cated to depict involved lymph nodes in the whole body and to
assess the metabolic activity of the primary neoplasm. The
recently proposed PERCIST system (PET Response Criteria
in Solid Tumours) evaluates changes in the standardised up-
take value (SUV) of 18FDG to assess treatment response [18].
Most of the above-mentioned imaging features could allow
distinguishing PPL from pancreatic adenocarcinoma, but the
differential diagnosis with autoimmune pancreatitis remains
difficult. As reported by previous authors, the size of the pa-
renchyma involved by the autoimmune process is smaller than
for PPL [3]. In addition, symptoms of autoimmune pancreati-
tis are less severe and the disease is often associated with
increased IgG4 serum levels [19]. According to our experi-
ence, it is mandatory to integrate imaging findings with the
clinical and laboratory results to make the correct diagnostic
hypothesis; histopathological confirmation is always neces-
sary, also to evaluate the lymphoma subtype.
The present study has some limitations, namely, its retrospec-
tive design and the relatively small sample size. A larger pro-
spective study would be required to corroborate our findings.
In conclusion, the most suggestive CT signs of primary
pancreatic lymphoma are a large hypodense mass lesion with
progressive contrast enhancement, absence of necrosis, lack
of dilation of the main pancreatic duct and presence of vessel
encasement without infiltration.
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